Rapid, Automated, At-Line Adenovirus Quantitation

Viral vector vaccines offer the advantage of a rapid response to emerging pathogens or even personalized cancer treatments.1 Adenoviruses (AV) represent one of the most versatile and well characterized viral vectors that have been used for clinical applications up to today. Besides their proven record of safety, one of their key advantages is the ability to trigger potent and long-lasting immunity that comprise humoral (antibody) as well as cellular immune (T-Cell) responses. Prominent representatives of adenoviral vector vaccines are the COVID-19 vaccines from Oxford/ AstraZeneca or Johnson & Johnson. However, analytical methods for the development and manufacturing of adenoviral biopharmaceuticals are still challenging and require continuous improvement to facilitate fast and reliable vector quantification and functional assessment.

White Paper from